SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|(Address of principal executive offices)||(Zip Code)|
Registrant’s telephone number, including area code:
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of exchange
on which registered
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01.|| |
Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference is the form of a shareholder presentation to be used by Cibus, Inc. (“Cibus”) in discussions with certain of its securityholders and other persons.
|Item 8.01.|| |
As of May 31, 2023, the number of shares of issued and outstanding common stock of Cibus was as set forth below.
Excluding restricted stock issued under the Cibus, Inc. 2017 Omnibus Incentive Plan, Cibus shares outstanding are:
21,225,234 shares of common stock, comprising:
16,582,599 shares of Class A common stock, par value 0.0001 per share (“Class A Common Stock”) and
4,642,635 shares of Class B common stock, par value 0.0001 per share, which are generally exchangeable, as a paired unit together with an equal number of Cibus Global, LLC membership units, for shares of Class A Common Stock on a one-for-one basis.
In addition, 1,019,282 restricted shares of Class A Common Stock granted pursuant to the Cibus, Inc. 2017 Omnibus Incentive Plan, which are subject to vesting, were issued and outstanding as of May 31, 2023.
|Item 9.01.|| |
Financial Statements and Exhibits.
The information furnished in Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
|99.1||Cibus, Inc. Shareholder Presentation (June 2023)|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, Cibus, Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 13, 2023
|Title:||Chief Executive Officer and Chairman|
Exhibit 99.1 Leading the Future of Breeding™ J u n e 2 0 2 3
Key Takeaways Cibus is a Pure-Play Trait Development Business Revolutionizing the Trait Royalty Industry Cibus’ Trait Machine is the Future of Traits: A Large Attractive Royalty Market Gene Edited Trait Development - Critical to the Agriculture Industry Near Term Royalty Patents & Patent Current Market Cibus Core Market Future Market Initial Crop & Applications Trait Platforms Opportunity Billions of Acres ~ 400MM Acres ~ 535 MM Acres 3 Crops/6 Traits $1.8B/~200MM acres > 1,000 $2 to $15 Per Acre ~ $8 Billion ~ $4 Billion • Technology - Merger with Calyxt Combines Leading Technologies • Large, Multi-billion $ Addressable Market - Together > 1,000 Patents & Patent Applications - GMO-Based Traits for weeds & insects on 300MM+ - Both Companies have Leading Traits & Programs acres in NA & SA are generating ~$8 Billion in Trait Fees • Business - Growing Need due to Changing Environmental Conditions - Portfolio of 6 initial traits that improve yields, - Growing addressable market as global regulators move lower costs and address climate goals to institutionalize regulations supporting gene editing - 3 Developed Traits in Canola & Rice that are shipping - Agreements with leading seed companies Note: See slide 25 below for term definitions, data sources & assumptions. Current market consists primarily of Traits developed using GMO technologies.
Key Management Rory Riggs Greg Gocal, PhD Peter Beetham, PhD COO, PRESIDENT CEO, CHAIRMAN EVP, CHIEF SCIENTIFIC CO-FOUNDER CO-FOUNDER OFFICER, CO-FOUNDER Noel Sauer, PhD Wade King, MD Travis Frey, PHD CHIEF FINANCIAL SVP, HEAD OF R&D EVP, SUSTAINABLE OFFICER INGREDIENTS, STRATEGY, 3 3 3
Breeding is How Seed Co’s Develop Traits The Seed Industry: Productivity Traits are the Primary Basis for Competition. Seed Co’s Charge Productivity Trait Fees for Productivity Gains from Traits. Conventional Trait Development (Breeding!) has Severe Scale & Speed Limitations 4
Cibus’ Trait Machine Changes the Game Standardized End-to-End Semi-Automated Gene Edited Trait Production Facility Trait Development in a Fraction of the Time and Cost of Conventional Breeding “Nature Identical” Traits Non-GMO Traits that are Cibus conventional breeding like. Bio-Mfg. Standards Pharma Standard Quality Control & Assurance. High Throughput Gene Editing System Timebound, Predictable & Reproducible Breeding System. RTDS 5
Trait Machine is a Step Change in Trait Development Transforms: 1) Trait Development, and 2) Trait Commercialization! 1– Prototyping Runs: Accelerates Proof of Concept, Development. 2– Production Runs: Accelerates Speed to Market, Commercialization. Once a trait is developed, Trait Machine directly Trait Machine Trait Machine accelerates edits a customer’s accelerates prototyping or time to commercialization. testing of different traits. elite germplasm. 6
The New Face of Trait Development Timebound, Reproducible and Predictable Trait Development Process Each Successive Stage Materially Increases the Probability of Next Stage and Successful Field Validation 7
Addresses the Pressing Need From Climate Change Billions of Acres being hit by Changing Diseases, Pests & Resources Desperate Need for Change in the Time Required and Scale of Trait Development Gene Editing is Virtually the Only Tool that Can Address Climate Challenges at Scale 8
Climate Need is Driving Regulatory Change Global Push: Regulate Gene Editing Like Conventional Breeding New Gene Editing Regulations in Place Positive Policy Processes Underway Positive Policy Discussions Note: Cibus traits are developed without integrating foreign DNA in the process or product. in key target markets including the United States, the new gene editing regulations are specifically separating Cibus traits from GMO (Genetically Modified Organisms) and regulating Cibus Traits similarly to traits from conventional breeding. 9
The Market Opportunity The Business, Product and Economic Opportunity of Plant Traits
Productivity Traits are a Royalty Business Royalties are Paid for Traits that Make Farmers Money - Improved Yields, Increased Productivity, and/or Lower Costs (Chemicals!) Trait Economics 1) Total Crop Acres 1) Crop Market (Acres) 2) Accessible Acres 2) Accessible Acres 3) Trait Fees/Royalties 3) Trait Fees/Royalties ($’s per bag or acre) - $’s per bag (or acre) Trait Royalty Market - $$$ “Traits by Acres by Trait Fees” Note: See slide 25 for term definitions, data sources & assumptions.
Example: The “Bt” Trait Trait: A “Bt” Protein that is Engineered into a Plant to make it Toxic to Plant specific pests. Economics: Bt Trait Increases productivity by killing pests, decreasing pesticide use & increasing yields. Crop Trait Fee (per acre) Pest Note: See slide 25 for term definitions, data sources & assumptions.. Annual Trait Fees (Revenues) $2.6 B $0.5 B $0.7 B (by Crop 2020 est.)
Business Model: Traditional Trait Distribution Model: Traits Distributed in Seeds by Seed Co’s Seed Co’s Pay Trait Royalties based on Trait Fees Paid by Farmer TURN TO WHO TURN TO Farmers Seed Companies Trait Developers Challenged by the impacts of Environment & Climate change Seed Co’s sell Farmer seeds with Develop Productivity Traits traits to address productivity needs. - License Trait IP to Seed Co’s. Farmers pay Seed Co’s trait fees Collect Royalties: (in total cost charged for seed) - Seed Co’s pay Trait Royalties for Trait IP based on Trait Fees. 13 13
Cibus’ Initial Crops Cibus’ Initial Business Model is 3 Crops: Canola, Rice & Soybean Canola Rice Soybean MM MM MM MarkSoybean et Market Market 10 ACRES 28 188 ACRES ACRES Lead Customer: Nuseed Lead Customer: Nutrien Lead Customer: GDM Traits Royalties ~$5-$15 Traits Royalties Traits Royalties ~$5-$15 ~$10-$30 (per acre) (per acre) (per acre) Note: See slide 25 for term definitions, data sources & assumptions. Market acres are for North America, South America & Australia Soybean Platform expected to be operational in H2 2023. 14
Cibus’ Initial Productivity Traits Cibus’ Initial Business Model is 6 Traits (in 3 Crops: Canola, Rice & Soybean) Crop Market Acres (MM) (Est. total crop acres in specific geographies.) Accessible Acres (MM) Canola, Rice, Soybean (Est. acres where the specific trait is needed.) ~250 MM Acres Developed & Shipping Advanced Note: Market and Accessible Acres are based on Canola, Rice, Soybean in N.A.,S.A, Europe Australia. 15 Est. Market Acres, Accessible and Trait Royalty Market for PSR are based on non-BASF acres. See slide 25 below for term definitions, data sources & assumptions.
Cibus’ Target Crops Include Corn & Wheat Cibus’ Target is the 5 Major Crops: Adding Corn & Wheat to Canola, Rice & Soybean $4.25 Billion Canola, Rice, Soybean, Wheat & Corn > 500 MM Est. Trait Acres Royalty Mkt. (All 5 Crops) Nutrient Use Efficiency Note: See slide 25 for term definitions, data sources & assumptions. Trait Royalty Market estimates are for Cibus’ initial 6 Traits in: 1) Canola, Rice, Soybean, Wheat & Corn, and in 2) NA, SA & Europe
st Lead 1 Trait: PSR: Pod Shatter Reduction - Canola/WOSR Trait Fees Acres (est.): ~26 MM, Trait Royalty Market (est.): ~$200 MM Reducing Pod Shatter Strong Commercial Progress: Sclerotinia Increases Oil Seed Yield Developed & Shipping POD Shatter Reduction Resistance . Strengthens Sheath that Initial Customers 10 Holds the Oil Seeds Initial Trait Acres (est.) ~15 MM Sheaths Shatter in Rain/High Wind Causing Trait Royalties (per acre) $5-$10 Yield Losses of 10% or More. Trait Royalties (per acre) $5-$10 ~$100 MM Trait Royalty Mkt (est.) Trait Royalty Mkt (est.) ~$100 MM (Initial 10 Customers) (Initial 10 Customers) Note: See slide 25 for term definitions, data sources & assumptions. Initial Trait Acres are based current customers in Canola in N.A., EU 1st Shipment Q1 2023 1st Transfer Q1 2023 17 17 Photo credit to the Canola Council of Canada
st Our 1 Blockbuster Trait Sclerotinia White Mold Resistance - Canola, Soybean Trait Royalty Market (est.): ~$650 MM Canola/ Soybean Sclerotinia Resistance WOSR Stage of Development Increases Yields, Sclerotinia Resistance Reduces Fungicide use Molecular Discovery Yes Yes Builds internal defenses to prevent Initiate Editing 2021 2023 Sclerotinia from infecting plant. Green House Confirmation 2022 NA . Improves Yields and Field Validation (est.) 2024 NA Reduces Use/Cost of Fungicides ~30 MM Accessible Acres (est.) ~50 MM Trait Royalties (est. per acre) ~$5-$10 ~$5-$10 Note: See slide 25 for term definitions, data sources & assumptions. Accessible Acres are for Sclerotinia in Soybean or Canola in N.A., S.A. and Europe. Trait Royalty Market ~$270 MM ~$385 MM Disease Resistance is a complex trait consisting of multiple modes of action.. (est.) st Cibus had green house confirmation of its 1 MOA of the trait in 2022 & nd the 2 MOA in 2023. 18 18 Photo credit to the Canola Council of Canada
Initial Crop: Canola Four of the Initial Six Traits will Be Traits Launched In Canola st Canola is Cibus’ 1 Operational Crop Platform, Royalty Potential - Initial Traits > $900 MM Cibus Trait Royalty Trait Royalty Initial Traits Market (est.) Accessible Acres (est.) (est. per acre) ~$200 MM Pod Shatter (PSR) 26 MM $5-$10 Sclerotinia Resistance ~$270 MM 30 MM $5-$10 Canola Herbicide Tolerance #2 (HT2) 20 MM $5-$10 ~$225 MM OSR 46 MM ~46 MM Acres Nutrient Use Efficiency (NUE) Nutrient Use Efficiency (NUE) ~$250 MM 46 MM $5-$15 Note: See slide 25 for term definitions, data sources & assumptions. Sclerotinia, HT#2 & NUE Accessible Acres are for the specific traits in Canola in N.A., S.A., Europe, & Australia are Multi-Crop Traits 19 19 19
Initial Crop: Rice Three of the Initial Six Traits will be launched in Rice nd Rice is Cibus’ 2 Operational Crop Platform, Royalty Potential - Initial Traits ~120 MM Cibus Trait Royalty Trait Royalty Initial Traits Market (est.) Accessible Acres (est.) (est. per acre) HT1, HT3 ~$100 MM 4 MM $10-$30 N Hut erb rie ici nt de UT se olera Effici nce # ency 2 (N (HU TE) 2) ~$21 MM 4 MM $5-$10 Rice ~10 MM Acres 46 MM Nutrient Use Efficiency (NUE) Note: See slide 25 for term definitions, data sources & assumptions. Sclerotinia, HT#2 & NUE Accessible Acres are for the specific trait in Rice in N.A., S.A. & Europe are Multi-Crop Traits 20 20 20
Initial Crop: Soybean Two of the Initial Six Traits will be launched in Soybean nd Soybean Expected to be Cibus’ 3 Operational Crop Platform, Royalty Potential - Initial Traits ~$800 MM Cibus Trait Royalty Trait Royalty Initial Traits Market (est.) Accessible Acres (est.) (est. per acre) ~$385 MM Sclerotinia Resistance 50 MM $5-$10 Herbicide Tolerance #2 (HT2) Herbicide Tolerance #2 (HT2) ~$420 MM 74 MM $5-$7 Soybean ~188 MM Acres 46 MM Nutrient Use Efficiency (NUE) Note: See slide 25 for term definitions, data sources & assumptions. Sclerotinia, HT#2 & NUE Accessible Acres are for in the specific trait in Soybean in N.A., S.A., Europe are Multi-Crop Traits Soybean platform expected to be operational in 2H 2023 Platform 21 21 21
Sustainable Ingredients Addresses Global Drive to Transition Ingredients to meet Corporate Sustainability Objectives P&G Collaboration: A Model for Co’s with Climate 2040 Sustainability Goals Proctor & Gamble In Q1-2023, Cibus and P&G entered into a collaboration to develop sustainable low carbon ingredients. - P&G will fund a multi-year program to develop Sustainable Low Carbon Ingredients that help advance its sustainability objectives. - Working with Cibus to Build a broader coalition. - Soybean is Key Crop for the Sustainable Ingredients Industry.
Future: “Core” Multi-Crop Productivity Traits Traits that Address > 100 MM Acres with Trait Royalties of $5 to $15 per acre Blockbusters are Traits that Address Agricultural Sustainability at Scale Target Areas Resistance Traits Efficiency Traits Sustainable Ingredients CLIMATE CHANGE PLANT OUTPUTS Addressing the impacts of climate Renewable products that don’t such as drought & weather negatively impact the environment during production, use, or disposal. NUTRIENT PROCESSING Able to better process available PROCESS OUTPUTS nutrients. Reduces fertilizer needs. Replacing inputs or process materials that negatively impact the environment. AGRONOMY Physiological traits that improve yields and farmability 23 23
2023 Highlights & Key Milestones Trait Royalty Market in Canola, Rice and Soybean for PSR, Sclerotinia, H1, HT2 & HT3 is: ~$1.5 Billion In Canola/WOSR alone, the Trait Royalty Market for PSR, HT2 and Sclerotinia is: ~$700 Million Trait Products Soybean Canola - Shipments: Six PSR Trait Transfers - Complete Platform Development st (1 Transfer in Q1 2023) (H2 2023) - Green House Data: HT2 (H2 2023), - Initiate Edits: HT2, Sclerotinia Sclerotinia (2022, H1 2023 & H2 2023) (H2 2023) - Initiate Edits: Nutrient Use Efficiency Wheat, Corn (H2 2023) - Wheat Platform Q4 2024 - Corn Platform Q4 2025 Rice - Shipments: Two HT Trait Transfers Operations (HT1 & HT3 Transfers in Q2 2023) - Initiate Edits: Nutrient Use Efficiency Trait Machine (Q1 2023) - “Oberlin” Operational H2 2023
Disclaimer Securities Law Matters Trade names, trademarks and service marks of other companies that appear are the property This presentation has been prepared by Cibus Global, LLC (the Company ), and the Company of their respective holders and do not imply a relationship with, or endorsement or is responsible for its contents. It shall not constitute an offer, nor a solicitation of an offer, of sponsorship of us, by these other companies. Solely for convenience, trademarks and trade the sale or purchase of securities, nor shall any securities of the Company be offered or sold, names in this presentation appear without the™ and ® symbols, but any such failure to in any jurisdiction in which such an offer, solicitation or sale would be unlawful. Neither the appear should not be construed as indicating that their respective owners will not assert their Securities and Exchange Commission nor any state securities commission has approved or rights with respect thereto. Cibus has over 400 patents issued or filed. disapproved of the transactions contemplated hereby or determined if this presentation is truthful or complete. Any representation to the contrary is a criminal offense. Industry and Market Data Information about market and industry statistics contained in this presentation is included 1. Comp Devel anyo Data, ped mea Projns ect va ioln id sa & ted Tefi rm els d trials (Canola PSR, rice HT1, HT3); Advanced based on information available to the Company that it believes is accurate in all material development means editing process underway with known edit targets. respects. It is generally based on academic and other publications that are not produced for 2. Bt refers to Bacillus thuringiensisthatis a species of bacteria that lives in soil purposes of securities offerings or economic analysis. The Company has not reviewed or included data from all sources, and the Company cannot assure potential investors of the 3. Total Market Acres and Accessible Acres are company estimates based on accuracy or completeness of the data included in this presentation. Forecasts and other industry sources. There can be no assurance that Accessible Acres can be achieved. forward-looking information obtained from these sources, including estimates of future 4. Trait Machine Platforms are operational in canola and rice. Soybean is expected to market size, revenue and market acceptance of products and services, are subject to the same be operational in H2 2023. qualifications and the additional uncertainties accompanying any forward-looking statements. 5. Trait Royalty Market is determined by multiplying the Est. Accessible Acres by the Acreage Data Est. Trait Fees for a specific Cibus trait in a specific geography or geographies. This presentation has 2 available acreage calculations: TAM-Total Accessible Acres and Trait 6. Shipping means traits are transferred to customers in a customer’s elite germplasm. Fees Acres. These are based on the company’s estimate of total hybrid acres available in: North America, South America & Europe for each crop. European acres are not currently 7. MOA refers single mode of action for a complex trait. accessible. These acres depend on a favorable outcome of the current EU Parliamentary 8. Complex traits refers to traits consisting of multiple modes of action. Greenhouse process. They are shown to show the potential increase in available acres if the EU were to confirmation of a complex trait may refer to a single MOA or Multiple MOA’s. pass the proposed legislation. The EU is expected to advance its legislative process for its proposed legislation. 9. cro Initp iate s. TE hey ditsma mean y besfor that atshe ing ed leiM tin OA g por roces Multi s ha plsebM eg O u A n’sfor . the trait in the specific Intellectual Property 10. Greenhouse Data means greenhouse confirmation for a single mode action or multiple modes of action for a trait. “Cibus,” “RTDS,” “Rapid Trait Development System,” “FALCO,” “SU Canola,” “Nucelis,” “ASAP,” “A Different Breed,” “Trait Machine,” “Inspired by Nature,” “Driving Sustainable Agriculture,” rd 3 Party Data “Reshaping Crop Protection,” “Reinventing Trait Development”, “Timebound & Predictable”, “Driving Trait & Breeding Innovation”, “Future of Breeding”, the Cibus logo and other 1. Trait Fee information are 2020 estimates based on data from Agbioinvestor, US trademarks or service marks of Cibus appearing in this presentation are the property of Cibus. Gov., BCG & 3rd party consultants. Traits are predominantly GMO traits in North & South America. 25
Forward Looking Statements This presentation contains “forward-looking statements” within the meaning of applicable securities laws, including The Private Securities Litigation Reform Act of 1995. All statements, other than statements of present or historical fact included herein, including statements regarding the benefits of the merger, Cibus, Inc.'s ( Cibus ) operational and financial performance, and Cibus’ strategy, future operations, prospects and plans, are forward-looking statements. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “intend”, “expect,” “plan,” “scheduled,” “could,” “would” and “will,” or the negative of these and similar expressions. These forward-looking statements are based on the current expectations and assumptions of Cibus’ management about future events, which are based on currently available information. These forward-looking statements are subject to numerous risks and uncertainties, many of which are difficult to predict and beyond the control of Cibus. There are many factors that could cause Cibus’ actual results, level of activity, performance or achievements to differ materially from those expressed or implied by forward- looking statements, including factors related to: (i) risks associated with the possible failure to realize certain anticipated benefits of the transactions contemplated by the merger (the “Transactions”), including with respect to future financial and operating results; (ii) the effect of the completion of the Transactions on Cibus’ business relationships, operating results and business generally; (iii) the outcome of any litigation related to the merger agreement or Transactions; (iv) competitive responses to the Transactions and changes in expected or existing competition; (v) challenges to Cibus’ intellectual property protection and unexpected costs associated with defending Cibus’ intellectual property rights; (vi) increased or unanticipated time and resources required for Cibus’ platform or trait product development efforts; (vii) Cibus’ reliance on third parties in connection with its development activities; (viii) Cibus’ ability to effectively license its productivity traits and sustainable ingredient products; (ix) the recognition of value in Cibus’ products by farmers, and the ability of farmers and processors to work effectively with crops containing Cibus’ traits; (x) Cibus’ ability to produce high- quality plants and seeds cost effectively on a large scale; (xi) Cibus’ need for additional funding to finance its activities and challenges in obtaining additional capital on acceptable terms, or at all; (xii) Cibus’ dependence on distributions from Cibus Global, LLC to pay taxes and cover Cibus’ corporate and overhead expenses; (xiii) regulatory developments that disfavor or impose significant burdens on gene-editing processes or products; (xiv) Cibus’ ability to achieve commercial success; (xv) commodity prices and other market risks facing the agricultural sector; and (xvi) technological developments that could render Cibus’ technologies obsolete. In addition to these factors, other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause Cibus’ actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Should one or more of these risks or uncertainties occur, or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. In addition, the forward-looking statements included in this press release represent Cibus' views as of the date hereof. Cibus specifically disclaims any obligation to update such forward- looking statements in the future, except as required under applicable law. These forward-looking statements should not be relied upon as representing Cibus' views as of any date subsequent to the date hereof.